## **MEDICAMEN Biotech Limited**



Regd. & Corp. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 (INDIA) Tel.: 011 - 47589500-51 (50 Lines), E-mail: info@medicamen.com Web: www.medicamen.com CIN No.: L74899DL1993PLC056594

Ref: STEX/DEV Report/2023-24

Date- 30.05.2023

**BSE Limited** 

Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400001

Scrip Code-531146

**National Stock Exchange of India Ltd** 

Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051

Symbol- MEDICAMEQ

Sub: Statement for Deviation(s) or Variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended March 31, 2023

Dear Sir/Madam,

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/ 162/2019 dated December 24, 2019; please find enclosed herewith Statement of deviation(s) or variation(s) of funds raised through preferential issue by the Company in the specified format, for the quarter ended March 31, 2023. The same has been reviewed by the Audit Committee of the Company on 29.05.2023.

This for your information and records

Thanking you,

Yours faithfully

For Medicamen Biotech Limited

Parul Choudhary
Company Secretary & Compliance Officer
ACS- 44157

Statement of Deviation / Variation in utilization of funds raised						
Name of listed entity						
Mode of Fund Raising	Preferential					
	Issues					
Date of Raising Funds	12.09.2022					
Amount Raised	Rs. 35,30,82,000					
Report filed for Quarter ended	31.03.2023					
Monitoring Agency	applicable / not applicable					
Monitoring Agency Name, if applicable						
Is there a Deviation / Variation in use of funds raised	<del>Yes</del> / No					
If yes, whether the same is pursuant to change in terms of a contract	NA					
or objects, which was approved						
by the shareholders						
If Yes, Date of shareholder Approval	NA					
Explanation for the Deviation / Variation	NA					
Comments of the Audit Committee after review	There is no deviation/variati					
	on in					
	the utilization of					
Comments of the auditors, if any	funds NA					
Objects for which funds have been raised and where	NA					
there has been a deviation, in the following table	INA					
Original Object	Modified Object,	Original	Modified	Funds	Amount of	Remarks ifany
	if any	Allocation	allocation ,if any	Utilized	Deviation/Va riation forthe quarter according to applicable object	·
a. The proceeds of the preferential issue shall be utilized to meet funding requirement for creating it's own marketing network in ten Francophone countries i.e., Ivory Coast, Ghana, Senegal, Cameroon, Burkina Faso, Benin, Togo, Niger, Mauritania and Mali by using distributing network of Euro Pharma, Paris.  b. MBL will market 100 branded products in each country of this	Not Applicable	Rs. 31,93,15,875	Not Applicable		Not Applicable	-

territory for which the brands have been finalized.					
c. MBL will file 100 dossiers in each of ten francophone countries making total 1000 dossier in all.					
d. MBL has already recruited a Country head (Africa) who is based Ghana, the marketing companies have also been shortlisted, who handle its marketing operation in these Francophone countries					
e. To augment the enhanced working capital requirement of the Company due to increase in scale of operations.					
Deviation or variation could mean:					
(a) Deviation in the objects or purposes for which the funds have been raised or					
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or					
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc					
Signature					
Paru	l Choudhary				
Name of Signatory					
Designation Composition Office	pany Secretary & Compliance cer				